<DOC>
	<DOCNO>NCT01370707</DOCNO>
	<brief_summary>The aim study evaluate efficacy safety fo CJ-30001/CJ-30002 .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety CJ-30001 CJ-30002 Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Subjects Type 2 Diabetes Mellitus 20~69 year old BMI &lt; 30kg/m2 HbA1c 7 % 11 % receive oral antihyperglycemic agent seven day least 8 week Willing adhere protocol requirement sign inform consent form Subjects Type 1 Diabetes Mellitus FPG &gt; 270mg/dL Subjects insulin treatment Subjects acute chornic metaboic acidosis Subjects cardiovascular disease Subjects chronic GI disease Subjects history substance alchol abuse within 1 year Subjects history hypersensitivity biguanide aGI Subjects hypopituitarism hypocorticalism Subjects cancer Subjects take corticosteriods plan take corticosteroid AST ALT &gt; 2.5 time upper limit normal Creatinine level &gt; 1.5mg/dL male 1.4mg/dL female SBP &gt; 150mmHg DBP &gt; 90mmHg Subjects work night shift Female subject pregnant , breastfeed use medically acceptable birth control Subjects participate study within 3 month Subjects judge unsuitable trial investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>